Zyxin promotes hepatocellular carcinoma progression via the activation of AKT/mTOR signaling pathway.
AKT/mTOR
Hepatocellular carcinoma
Invasion
Migration
Proliferation
Zyxin
Journal
Oncology research
ISSN: 1555-3906
Titre abrégé: Oncol Res
Pays: United States
ID NLM: 9208097
Informations de publication
Date de publication:
2023
2023
Historique:
received:
25
02
2023
accepted:
17
05
2023
medline:
8
8
2023
pubmed:
7
8
2023
entrez:
7
8
2023
Statut:
epublish
Résumé
Hepatocellular carcinoma (HCC) is a common malignancy that is driven by multiple genes and pathways. The aim of this study was to investigate the role and specific mechanism of the actin-interacting protein zyxin (ZYX) in HCC. We found that the expression of ZYX was significantly higher in HCC tissues compared to that in normal liver tissues. In addition, overexpression of ZYX in hepatoma cell lines (PLC/PRF/5, HCCLM3) enhanced their proliferation, migration and invasion, whereas ZYX knockdown had the opposite effects (SK HEP-1, Huh-7). Furthermore, the change in the expression levels of ZYX also altered that of proteins related to cell cycle, migration and invasion. Similar results were obtained with xenograft models. The AKT/mTOR signaling pathway is one of the key mediators of cancer development. While ZYX overexpression upregulated the levels of phosphorylated AKT/mTOR proteins, its knockdown had the opposite effect. In addition, the AKT inhibitor MK2206 neutralized the pro-oncogenic effects of ZYX on the HCC cells, whereas the AKT activator SC79 restored the proliferation, migration and invasion of HCC cells with ZYX knockdown. Taken together, ZYX promotes the malignant progression of HCC by activating AKT/mTOR signaling pathway, and is a potential therapeutic target in HCC.
Identifiants
pubmed: 37547758
doi: 10.32604/or.2023.029549
pii: 29549
pmc: PMC10398406
doi:
Substances chimiques
Proto-Oncogene Proteins c-akt
EC 2.7.11.1
TOR Serine-Threonine Kinases
EC 2.7.11.1
Zyxin
0
ZYX protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
805-817Informations de copyright
© 2023 Cai et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest to report regarding the present study.
Références
Crit Rev Biochem Mol Biol. 2013 May-Jun;48(3):222-72
pubmed: 23547785
J Nutr Biochem. 2021 Mar;89:108556
pubmed: 33249185
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Cancer Res. 2021 Jan 15;81(2):315-331
pubmed: 33067265
Prog Neurobiol. 2021 Sep;204:102089
pubmed: 34118354
Anticancer Res. 2020 Nov;40(11):5981-5988
pubmed: 33109535
Cells. 2020 Dec 09;9(12):
pubmed: 33317149
J Invest Dermatol. 2002 Feb;118(2):246-54
pubmed: 11841540
J Gastrointest Surg. 2013 Sep;17(9):1600-8
pubmed: 23780638
Oncotarget. 2017 Jan 17;8(3):4543-4548
pubmed: 27965464
Eur J Med Chem. 2020 Oct 1;203:112571
pubmed: 32707525
Front Oncol. 2020 Feb 07;10:58
pubmed: 32117722
Cancers (Basel). 2017 Sep 20;9(9):
pubmed: 28930164
Cancer Lett. 2020 Feb 28;471:125-134
pubmed: 31830561
Cancers (Basel). 2015 Jan 23;7(1):179-237
pubmed: 25625291
J Cell Sci. 2003 Nov 15;116(Pt 22):4605-13
pubmed: 14576354
Onco Targets Ther. 2018 Dec 03;11:8633-8642
pubmed: 30584322
Mol Oncol. 2022 Apr;16(7):1555-1571
pubmed: 34826187
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Nat Commun. 2016 Mar 31;7:11123
pubmed: 27030211
J Hepatocell Carcinoma. 2016 Oct 05;3:41-53
pubmed: 27785449
Hepatol Res. 2019 Oct;49(10):1097-1108
pubmed: 31009153
Cell Death Dis. 2017 Mar 30;8(3):e2706
pubmed: 28358369
Int J Mol Sci. 2021 Mar 05;22(5):
pubmed: 33808029
Mol Oncol. 2020 Jun;14(6):1365-1380
pubmed: 31944556
Mol Cell. 2017 Feb 2;65(3):380-392
pubmed: 28157503
Toxicol Appl Pharmacol. 2021 Sep 1;426:115593
pubmed: 34038713
Front Oncol. 2021 Feb 26;11:607021
pubmed: 33718159
Bioengineered. 2021 Dec;12(1):1826-1837
pubmed: 33975512
Int J Oncol. 2013 Mar;42(3):873-80
pubmed: 23292068
Trends Cell Biol. 2014 Oct;24(10):575-83
pubmed: 24933506
Proc Natl Acad Sci U S A. 2018 Feb 27;115(9):E2030-E2039
pubmed: 29440488
Sci Rep. 2019 Sep 9;9(1):12908
pubmed: 31501460
FEBS J. 2019 Sep;286(18):3510-3539
pubmed: 31330086
Biochem Pharmacol. 2019 Dec;170:113676
pubmed: 31647925
Lab Invest. 2020 Jun;100(6):812-823
pubmed: 31949244
J Control Release. 2022 Sep;349:213-226
pubmed: 35793737
Bioengineered. 2021 Dec;12(2):11728-11739
pubmed: 34784846
Acta Pharm Sin B. 2022 Feb;12(2):558-580
pubmed: 35256934
J Cell Physiol. 2019 Sep;234(9):15775-15789
pubmed: 30697742
PLoS Biol. 2011 Jun;9(6):e1000624
pubmed: 21666802
iScience. 2020 Oct 15;23(11):101690
pubmed: 33163943